Click Therapeutics
Click Therapeutics Leadership & Management
What People Are Saying About Click Therapeutics
-
Strategic Vision & Planning: Leadership consistently articulates a two‑pillar model—stand‑alone PDTs and Software‑Enhanced Drugs—reiterated by the CEO in 2024/2025 and reflected in ongoing messaging about drug‑plus‑software prescribing. Recent moves like the Click SE launch and the continued CNS/migraine focus reinforce a coherent, repeated direction.
-
Strong Execution: Multiple FDA milestones and deal steps match the stated plan, including Rejoyn’s 2024 clearance, CT‑132’s 2025 De Novo authorization, and the April 9, 2026 agreement and funding to advance CT‑155 toward market. These actions indicate follow‑through from strategy to tangible progress.
-
Collaborative & Aligned Leadership: A partner‑centric path is evident through alliances with Otsuka and Boehringer, as well as platform collaborations like Dassault/Medidata and the 2026 Ultrahuman tie‑up in migraine. The CT‑155 restructuring with Boehringer aligns governance and funding with Click’s shift toward greater commercial ownership.
Click Therapeutics's Benefits
Hosts in-person all-hands meetings
Implements team-based strategic planning
Open office floor plan to encourage communication and collaboration
Uses an OKR operational model to clearly define goals and priorities
Utilizes an open door policy that encourages accessibility
